Evidence map›Paper›PMID 34736533›Full record

SynthesisAntimicrobial resistance and infection control2021

The effect of eye protection on SARS-CoV-2 transmission: a systematic review.

Oyungerel Byambasuren, Elaine Beller, Justin Clark, Peter Collignon, Paul Glasziou

Abstract readSystematic Review
In one paragraph

Synthesis in Antimicrobial resistance and infection control, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Eyeglasses and risk of COVID-19 transmission-analysis of the Virus Watch Community Cohort study.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2024
    Article
  10. Review
  11. Review
  12. Review
  13. SARS-CoV-2 in brief: from virus to prevention.Osong public health and research perspectives · 2022
    Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Oyungerel ByambasurenInstitute for Evidence-Based Healthcare, Bond University, 14 University Dr, Robina, QLD, 4226, Australia. obyambas@bond.edu.au.ORCID 0000-0002-8641-1286
Elaine BellerInstitute for Evidence-Based Healthcare, Bond University, 14 University Dr, Robina, QLD, 4226, Australia.
Justin ClarkInstitute for Evidence-Based Healthcare, Bond University, 14 University Dr, Robina, QLD, 4226, Australia.
Peter CollignonMedical School, Australian National University, Canberra, ACT, Australia.
Paul GlasziouInstitute for Evidence-Based Healthcare, Bond University, 14 University Dr, Robina, QLD, 4226, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe effect of eye protection to prevent SARS-CoV-2 infection in the real-world remains uncertain. We aimed to synthesize all available research on the potential impact of eye protection on transmission of SARS-CoV-2.

methodsWe searched PROSPERO, PubMed, Embase, The Cochrane Library for clinical trials and comparative observational studies in CENTRAL, and Europe PMC for pre-prints. We included studies that reported sufficient data to estimate the effect of any form of eye protection including face shields and variants, goggles, and glasses, on subsequent confirmed infection with SARS-CoV-2.

resultsWe screened 898 articles and included 6 reports of 5 observational studies from 4 countries (USA, India, Columbia, and United Kingdom) that tested face shields, goggles, and wraparound eyewear on 7567 healthcare workers. The three before-and-after and one retrospective cohort studies showed statistically significant and substantial reductions in SARS-CoV-2 infections favouring eye protection with odds ratios ranging from 0.04 to 0.6, corresponding to relative risk reductions of 96% to 40%. These reductions were not explained by changes in the community rates. However, the one case-control study reported odds ratio favouring no eye protection (OR 1.7, 95% CI 0.99, 3.0). The high heterogeneity between studies precluded any meaningful meta-analysis. None of the studies adjusted for potential confounders such as other protective behaviours, thus increasing the risk of bias, and decreasing the certainty of evidence to very low.

conclusionsCurrent studies suggest that eye protection may play a role in prevention of SARS-CoV-2 infection in healthcare workers. However, robust comparative trials are needed to clearly determine effectiveness of eye protections and wearability issues in both healthcare and general populations.

Indexed as

Eye Protective DevicesCommunicable Disease ControlCOVID-19HumansInfectious Disease Transmission, Professional-to-PatientPandemicsSARS-CoV-2COVID-19Eye protectionFace shieldInfection preventionSARS-CoV-2

Identifiers

PMID34736533
PMCPMC8567128

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.